NSE: DIVISLAB · BSE: 532488 · ISIN INE361B01024
Divi's Laboratories Limited stock analysis
Divi's Laboratories Limited ranks #140 in the TickerSutra evidence-ranked universe with a score of 71/100 and 95% data confidence. The latest captured fundamentals show ROCE of 22.0%, quarterly sales growth of 27.8% and quarterly profit growth of 65.5%.Watchlist candidate
INVESTMENT EVIDENCE
What supports—and challenges—the thesis
Evidence in favour
- ROCE is 22%
- Low debt/equity of 0×
- Institutional ownership is rising
- CWIP indicates an active capacity pipeline
- No promoter shares are reported as pledged
Risks and constraints
- Valuation is above 40× earnings
Still unresolved: Related-party exposure · Broad media sentiment
FINANCIAL TRAJECTORY
Recent operating history
| Period | Revenue | Operating profit | Net profit | Operating margin |
|---|---|---|---|---|
| 2022 | ₹8,960cr | ₹3,885cr | ₹2,960cr | 43.0% |
| 2023 | ₹7,768cr | ₹2,370cr | ₹1,823cr | 31.0% |
| 2024 | ₹7,845cr | ₹2,210cr | ₹1,600cr | 28.0% |
| 2025 | ₹9,360cr | ₹2,973cr | ₹2,191cr | 32.0% |
| 2026 | ₹10,560cr | ₹3,442cr | ₹2,568cr | 33.0% |
| TTM | ₹11,230cr | ₹3,967cr | ₹2,925cr | 35.0% |
EXCHANGE EVENT TRIGGERS
Latest corporate disclosures
Divi's Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
RoutineDivis Laboratories Ltd - 532488 - Announcement under Regulation 30 (LODR)-Newspaper PublicationBSE · 12 Sept 2026Newspaper Clippings - Special Window for transfer and dematerialisation of physical shares
MANAGEMENT COMMENTARY
Signals from filed documents
Efforts made over the past several years to strengthen procurement resilience, diversify our global supplier base and expand domestic sourcing capabilities have continued to support manufacturing continuity across our network. These initiatives, together w ith our backward integration programmes, have enhanced supply assurance for several critical raw materials and Divi’s Laboratories Limited August 01, 2026 Page 5 o
So whatever you're seeing right now is a market correction based on the raw material prices that have taken a substantial hit. It's not based on the markets have corrected and the pricing pressure has gone down. Divi’s Laboratories Limited August 01, 2026 Page 11 of 17 Shyam Srinivasan: Got it.
Customer programmes continue to progress across multiple phases of development during the quarter , while qualification and validation activities for several peptides fragments are expected to advance over the coming quarters. Alongside capacity expansion in both solid-phase and liquid-phase peptide synthesis, we continue to strengthen the process development, analytical and manufacturing capabilities required for in
forex transactions and translations amounting to ₹210 crores against a gain of ₹48 crores in previous year. Particulars FY 2025-26 FY 2024-25 Exports 89% 88% Imports, including supplies from SEZ units 44% 49% Top 5 products 48% 43% Top 5 customers 51% 49% Exports in USD terms 86% 86% Exports in Pounds 8% 9% Exports in Euro 6% 5% 7. Performance and operations review Analysis of profitability of Indian Operations for t
Regional Market Structure [6] • North America remains the largest market, accounting for over 40% of global pharmaceutical value in 2025, supported by high R&D intensity, rapid adoption of innovative therapies, advanced healthcare and reimbursement infrastructure, and high per capita drug spending. • Europe represents a stable, regulation-driven market, contributing ~22–25% of global pharma value, with strengths in b
Over the past nine years, it has grown at a CAGR of ~9%[10] and contributes ~1.7% to national GDP [2], firmly establishing itself as one of India’s most globally competitive manufacturing sectors. With the domestic market growing above 8% to reach ~USD 25.8 billion (` 2.46 lakh crore) [11] and exports maintaining strong momentum, the pharmaceutical industry surpassed USD 55 billion in FY26, underscoring its strength
We are actively engaged with several Big Pharmas across Phase I, Phase II and Phase III programmes, and as these molecules advance through regulatory milestones, we are ready to scale investments and capacity to meet their demand. BUSINESS MODEL Where Chemistry Meets Value Creation Core Activities We operate across the entire pharmaceutical value chain, from research & development to commercial production, ensuring t
Within Custom Synthesis, projects actively continued across all diverse portfolio of customer programmes covering multiple therapeutic areas and stages of development. We are supporting customers across clinical development, validation and commercial supply preparations , with manufacturing activities are aligned to individual regulatory and filing requirements. Likewise, the three major capex programmes are nearing
So given this tailwind that we have already witnessed, so can you talk something about your margin trajectory, what -- if not on the number front, at least qualitatively going ahead in the current financial year? Nilima Prasad Divi: Currently, I would say that we did have quite a bit of increase in our raw material costs on various fronts. Mainly we saw it on the solvent side, which we never saw before.
The ratio will be higher in terms of CS because commercial volumes will start moving. So all this is subjected to all regulatory approvals. So we would just like to stick to the double digits.
So in India, there are a lot of companies are starting CDMO segment and they are consolidating into CDMO. But do you see any margin pressure in CDMO segment going forward? Or is there any indication from customers who are negotiating hard on pricing?
• The Company or its subsidiaries has not given any loans or advances to any firm / company in which its directors are interested. • During financial year, the Company has not raised any funds through preferential allotment or qualified institutional placement. • During the year under review, the Board of Directors has accepted all the recommendations of the Committees of the Board.
HOW TO READ THIS PAGE
Evidence, freshness and limitations
What does the TickerSutra score mean?
The score ranks captured evidence across financial quality, growth, moat and margins, regulatory catalysts, governance, institutional trend and valuation comfort. It is a research-prioritization tool—not a buy recommendation or price target.
Which sources support this page?
Financial history, ownership and pledge data, NSE and BSE filings, annual reports and available earnings-call transcripts are combined here. Use the source trail and original exchange document before relying on a decision-critical fact.
Why can an item be unresolved?
Unresolved means the current captured source window did not provide enough evidence for that check. It does not establish that a risk or relationship is absent.
Maintained by TickerSutra Research · Snapshot updated 29 Sept 2026 · Read the methodology · Read the disclaimer
DIRECTOR & BUSINESS NETWORK
Loading corporate intelligence
Loading universe coverage and exchange-backed evidence…